Obagi Medical (OMPI) Bidding War Could Take Stock as High as $27/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Valeant (VRX) May Tuck Tail if Obagi (OMPI) Bidding War Heats Up - Analyst
April 4, 2013 1:33 PM EDTYesterday Valeant Pharmaceuticals (NYSE: VRX) raised its offer for Obagi Medical Products, Inc. (NASDAQ: OMPI) from $19.75 to $24 per share, topping Merz's $22 per share bid. Commenting on the development, analyst David M Steinberg of Deutsche bank said he... More
Obagi Medical (OMPI) Acknowledges Merz Pharma Offer, Will Review
April 2, 2013 12:31 PM EDTOn April 2, 2012, Obagi Medical Products, Inc. (Nasdaq: OMPI) announced that the Obagi Board of Directors had received an unsolicited letter from Merz Pharma offering $22 per share cash to acquire the Company, and the Obagi Board of Directors will evaluate Merz Pharmas offer and... More
Merz Pharma Tops Valeant (VRX) Offer for Obagi Medical Products (OMPI), Offers $22/Share
April 2, 2013 7:51 AM EDTIn a letter to the Board of Directors of Obagi Medical Products, Inc. (NASDAQ: OMPI) Merz Pharma Group today outlined a proposal to acquire all of the outstanding common stock of Obagi for $22 per share in cash. This proposal represents a 58% premium to Obagi's closing share price on Thursday, March 14, 2013, the last trading day prior to the disclosure on Obagi's fourth quarter earnings call that Obagi had engaged a financial advisor to help explore "all opportunities."
On March 20, 2013, Obagi announced that it entered into a definitive merger agreement with Valeant Pharmaceuticals... More
